Product overview

Name Ritonavir
Alternative names ABT-538 , A-84538 , Abbot 84538
Purity >98%
Description HIV-1 and HIV-2 protease inhibitor
Write Your Own Review
You're reviewing:Ritonavir
Rate this item:

Biological Data

Biological description

HIV-1 and HIV-2 protease inhibitor, frequently used in immunometabolism research.

Potentially binds and inhibits the CEP_C30 (coronavirus endopeptidase C30) of SARS-CoV-2 and when used with lopinavir has shown to improve animal models of MERS-CoV.

Also shows antitumour activity and induces apoptosis.

Solubility & Handling

Storage instructions -20°C
Solubility overview Soluble in DMSO (20mM, gentle warming) and ethanol (10mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >98%
Chemical name 5-Thiazolylmethyl (3S,4S,6S,9S)-4-hydroxy-12-methyl-9- (1-methylethyl)-13-[2- (1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis (phenylmethyl)-2,7,10,12-tetraazatridecanoate
Molecular Weight 720.94
Chemical structure Ritovavir [155213-67-5] Chemical Structure
Molecular Formula C37H48N6O5S2
CAS Number 155213-67-5
PubChem identifier 392622
SMILES O[C@@H] (C[C@@H] (NC ([C@H] (C (C)C)NC (N (C)CC1=CSC (C (C)C)=N1)=O)=O)CC2=CC=CC=C2)[C@@H] (NC (OCC3=CN=CS3)=O)CC4=CC=CC=C4
InChi InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28
InChiKey NCDNCNXCDXHOMX-XGKFQTDJSA-N
MDL number MFCD00927142

References for Ritonavir

References are publications that support the biological activity of the product
  • Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

    Beck BR et al (2020) Comput Struct Biotechnol J 18 : 784-790
  • Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

    Chan JF et al (2015) J Infect Dis 212(12) : 1904-13
  • Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

    Zeldin RK et al (2004) J Antimicrob Chemother 53(1) : 44078

3 Item(s)